Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Laboratory Corp. of America Holdings    LH

Delayed Quote. Delayed  - 07/22 10:02:02 pm
138.82 USD   +0.68%
07/13 LABORATORY OF A : Healthcare Sector Equities Under the Scanner -- Ag..
07/01 LABORATORY OF A : Conversion Right Triggered for LabCorp’s Zer..
06/27 LABORATORY OF A : LabCorp Announces Launch of New Companion Diagnost..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Laboratory Corp. of America Holdings : LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/13/2012 | 10:05pm CEST

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2012 to September 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 7, 2012, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $1.50 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is August 26, 2012. The payment of contingent cash interest is expected to be made on September 11, 2012.

About LabCorp®

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its specialized labs and the LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine Sciences. LabCorp conducts clinical trials testing through its Esoterix Clinical Trials Services. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com.

This press release contains forward-looking statements. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2011, and subsequent SEC filings.

LabCorp
Stephen Anderson, 336-436-5274
www.labcorp.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LABORATORY CORP. OF AMERIC
07/20 LABORATORY OF AMERICA : Special Notice - Notice of Sole Source Award to Laborato..
07/20 LABORATORY OF AMERICA : Special Notice - Q-- Notice of Sole Source Award to Labo..
07/13 LABORATORY OF AMERICA : Healthcare Sector Equities Under the Scanner -- Agilent ..
07/01 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
07/01 LABORATORY OF AMERICA : Conversion Right Triggered for LabCorp’s Zero Coup..
06/30 LABORATORY OF AMERICA : Current List of HHS-Certified Laboratories and Instrumen..
06/27 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
06/27 LABORATORY OF AMERICA : LabCorp Announces Launch of New Companion Diagnostic for..
06/14 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
06/08 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
More news
Sector news : Healthcare Facilities & Services - NEC
07/21DJQUEST DIAGNOSTICS : Profit Rises, Helped by Lower Costs
06/28DJNestlé Turns to Health Sector for Next CEO -- WSJ
06/27 FRESENIUS SE KGAA : Nestle poaches CEO from Fresenius in health and wellness dri..
06/27DJNestle Taps Schneider as Next CEO -- Update
06/27DJNestlé Taps Schneider as Next CEO
More sector news : Healthcare Facilities & Services - NEC
News from SeekingAlpha
07/20 Transgenomic licenses heart rhythm test to LabCorp
07/15 These S&P 500 stocks have the most upside/downside vs. consensus - Wells Farg..
07/07 17 Silent Dividend Stocks For Long-Term Growth
07/03 These stocks should generate superior ROE and FCF - Barclays
06/27 Brexit kills the value trade, buy 'Stable Growers' - RBC
Advertisement
Financials ($)
Sales 2016 9 353 M
EBIT 2016 1 523 M
Net income 2016 753 M
Debt 2016 5 035 M
Yield 2016 -
P/E ratio 2016 18,63
P/E ratio 2017 15,97
EV / Sales 2016 2,06x
EV / Sales 2017 1,88x
Capitalization 14 215 M
More Financials
Chart LABORATORY CORP. OF AMERIC
Duration : Period :
Laboratory Corp. of Americ Technical Analysis Chart | LH | US50540R4092 | 4-Traders
Full-screen chart
Technical analysis trends LABORATORY CORP. ...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 144 $
Spread / Average Target 3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David P. King Chairman, President & Chief Executive Officer
Glenn A. Eisenberg Chief Financial Officer, Treasurer & Executive VP
Mark Elliott Brecher Chief Medical Officer & Senior Vice President
Lance V. Berberian Chief Information Officer & Senior Vice President
Marcia T. Eisenberg Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LABORATORY CORP. OF AM..12.28%14 215
HCA HOLDINGS INC18.81%31 421
FRESENIUS MEDICAL CARE..4.13%27 590
DAVITA HEALTHCARE PART..11.76%16 088
UNIVERSAL HEALTH SERVI..15.68%13 419
QUEST DIAGNOSTICS INC19.48%12 024
More Results